Manufacturer¿s ref.No: (b)(4).Information regarding patient identifier, date of birth, age, gender, weight, race, and ethnicity were not provided.Section d.2b: procode is nry/qjp.Section e.1: the name, phone and email address of the initial reporter are not available / reported.Based on complaint information, the device is not available to be returned for analysis.A review of manufacturing documentation associated with this lot (31194421) presented no issues during the manufacturing or inspection processes related to the reported complaint.There were no nonconformances related to device manufacture or inspection.Product analysis cannot be conducted as the product was not returned for analysis.No determination of causes and possible contributing factors could be made.As such, the investigation will be closed.With the information available and without the complaint product available to be returned for analysis, the reported product issue documented in the complaint cannot be confirmed through functional evaluation and analysis.Based on the manufacturing documentation review, there is no indication that the event is related to the device manufacturing process.Assignment of root cause for the event remains speculative and inconclusive, based on the limited information provided and without the return of the complaint device; however, it is possible that clinical and procedural factors, including device manipulation / interaction may have contributed to the reported failure.As part of the post market surveillance program, information from this complaint is trended for statistical signals and corrective / preventive action may be triggered at a later time.Since there was no evidence to suggest the event was related to a manufacturing or design issue, no corrective actions will be taken at this time.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by cerenovus, or its employees that the report constitutes an admission that the product, cerenovus, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Missing information from this report is identified as blank; this information was not provided in the reported event or available at the time of report submission.The manufacturer will submit a supplemental report if new facts arise which materially alter information submitted in a previous mdr report.Additional information will be submitted within 30 days of receipt.
|
The healthcare professional reported that during a mechanical thrombectomy procedure of the posterior circulation to treat a cerebral infarction, the cereglide 71 intermediate catheter (nic71132c / 31194421) was removed from the hoop and inserted into the patient¿s body.After advancing to the target lesion, aspiration was performed but no negative pressure could be applied.The cereglide catheter was removed from the patient¿s body and checked.The cereglide catheter was reportedly bent near the hub.It was replaced with a red 72 reperfusion catheter (penumbra) and the procedure was resumed to completion; it was reported that the procedure was completed with two passes and a tici score of 3 was achieved.The physician commented that the cereglide catheter may have been damaged during its removal from the hoop.There was no report of any negative patient impact.On 08-mar-2024, additional information was received.Per the information, there was no difficulty in removing the cereglide catheter from the device packaging.The procedure was an adapt (direct aspiration first pass technique) and the device could be advanced without any issue.The information indicated that there was a leakage of contrast observed.No further information could be obtained.Based on the additional information received on 08-mar-2024 that there was a leakage of contras medium, the event has been deemed usfda reportable under 21 cfr 803 with a classification of ¿malfunction.¿.
|